The Pennant Group Acquires Texas Home Health Provider

The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice, home care and senior living companies, today announced that it has acquired the assets of Cardiovascular Home Care, which provides home health services in Fort Worth, Texas.

The acquisition was effective May 1, 2021 and will operate under the name Custom Care Home Health.

“Having a strong hospice agency and a number of senior living communities in Dallas, we have carefully looked for the right opportunity to add home health services in the DFW area. This acquisition provides a strong platform for our local leaders to better address the needs of the community,” said Danny Walker, Pennant’s Chief Executive Officer. “Throughout our home health and hospice portfolio, there are dozens of opportunities like this to expand our services and be a solution for patients throughout the care continuum,” he added.

“This agency was founded by talented clinicians who believed in providing the highest standard of patient care,” commented Brent Guerisoli, President of Pennant. Noting that the agency admitted approximately 1,500 patients last year, Mr. Guerisoli added, “Their commitment to clinical excellence is demonstrated by their high quality ratings and strong market reputation. We are thrilled to welcome their talented team and look forward to continuing their tradition of outstanding patient care.”

Mr. Guerisoli reaffirmed that Pennant continues to pursue opportunities to acquire home health, hospice, home care and senior living businesses throughout the United States.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy

Exit mobile version